Boy Gets First of Kind Stem Cell Transplant Doctors at Beaumont Hospital in Royal Oak, Mich., led by Dr. Cindy Grines and Dr. William O'Neill, who suggested an experimental treatment. The patient, 16-year-old Dimitri Bonnville, had a massive heart attack after being shot in the heart with a nail gun. "This treatment was Dimitri's only option, aside from a heart transplant," says William O'Neill, M.D., Beaumont's chief of cardiology.
Cardio-Matrex ®
The Future of Cardio Therapeutics ®
The world’s first commercially produced- combination biologic therapeutic, combining human grade expanded adult stem cells, suspended within nano-matrix, hydrogels, and self-assembling nano-peptides.
Regenerating the damaged human heart therapeutically is the new paradigm that was a heresy not too long ago. Regenerative cardiology is now a segment of one of the most heavily funded areas of medical research in human history.
In its Second Coming the drug development industry is back with a vengeance to conquer the eluding dream. The rush to get a non-invasive heart repair drug is unprecedented.
Such a scale of drug development initiative for a single category of indication has no parallel or precedence in the healthcare industry. It's nothing less than the Gold Rush of 21st Century.
Cardio-Matrex is the most powerful and potent therapy that has ever been developed for patients affected by cardiovascular disease. It promises to be better than all the best drugs and interventional surgical therapies and is a godsend for the desperate and dying.
Heart disease, as we all know is the most prolific medical killer, affecting a reported 50 million individuals in the U.S. alone.
CardioMatrex Tissue Engineering Biologic
BEST Biotecnica to Launch India Medical Mission
More than 2 million Indians need, but cannot afford, heart surgery.
"But what percentage of people can afford it? If a solution is not affordable, it is not a solution." Dr Devi Shetty
India's no.1 killer: Heart disease
Largest-ever study of deaths shows heart ailments have replaced communicable diseases as the biggest killer in rural & urban India. Now researchers say India, a country with more than one billion people, will likely account for 60 per cent of heart disease patients worldwide.
The heart disease mutation carried by 60 million!
Indian scientists express this genetic risk as an odds ratio; where 1.2 would be a small effect and 2.0 a large one. For the MYBPC3 mutation, the odds ratio is almost off-scale, a staggering 7.0.
Carriers usually show few symptoms until middle age, but after that age most are symptomatic and suffer from a range of effects, at worst sudden cardiac death. The mutation almost guarantees the development of the disease and Indians suffer heart attacks at an earlier age, often without prior symptoms or warning.
Cardio-Matrex’s proprietary technology expands populations of cord blood stem cells to create a therapeutic dose to treat such patients. The expanded CD133 cells are combined with various tissue engineering jells, such as self-assembling nano-peptides; hydrogels, collagen, or nano matrix to create a completely non-invasive restorative therapeutic.
Cardio-Matrex is a tissue engineering product, capable of the regenerating aged and diseased heart tissues. Available for critically ill patients, this humanitarian lifesaving biologic, represents a quantum leap ahead of all competitors.
The Stem Cell Center – Texas Heart Institute
The Stem Cell Center – Texas Heart Institute is dedicated to the study of adult stem cells and their role in treating diseases of the heart and the circulatory system. Through numerous clinical and preclinical studies, we have come to realize the potential of stem cells to help patients suffering from cardiovascular disease. We are actively enrolling patients in studies using stem cells for the treatment of heart failure.
Whether you are a patient looking for information regarding our research, or a doctor hoping to learn more about stem cell therapy, we welcome you to the Stem Cell Center. Please visit our Clinical Trials page for more information about our current trials.
Emerson C. Perin, MD, PhD, FACC
Director, Clinical Research for Cardiovascular Medicine
Medical Director, Stem Cell Center
“For me, cardiology is the most exciting specialty in medicine. After being trained in a different specialty, I decided that cardiology and interventional cardiology were an ideal combination of my love of research, ability to work well with my hands and desire to benefit people’s lives. Also, the diseases that affect the heart and vasculature can be challenging, and I enjoy meeting challenges head-on. This is at the very center of my commitment to the people in my care. My goal is to provide the very best care for each individual, which is why it’s so important to me that I remain at the forefront of cardiovascular medicine and interventional cardiology. Through research, through innovation and by making a personal commitment to each patient, I’m able to offer real, meaningful and often immediate help. It’s rewarding to see tangible results, especially in the faces of the people who trust me to help them with problems that are real and often quite serious.”